These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The continuing crisis in antibiotic resistance. French GL Int J Antimicrob Agents; 2010 Nov; 36 Suppl 3():S3-7. PubMed ID: 21129629 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial resistance in internal medicine wards. Menichetti F; Tagliaferri E Intern Emerg Med; 2012 Oct; 7 Suppl 3():S271-81. PubMed ID: 23073868 [TBL] [Abstract][Full Text] [Related]
25. Approaches to reduce antibiotic resistance in the community. Cohen R Pediatr Infect Dis J; 2006 Oct; 25(10):977-80. PubMed ID: 17006310 [TBL] [Abstract][Full Text] [Related]
26. PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates. Solomon K; Fanning S; McDermott S; Murray S; Scott L; Martin A; Skally M; Burns K; Kuijper E; Fitzpatrick F; Fenelon L; Kyne L J Antimicrob Chemother; 2011 Sep; 66(9):1976-82. PubMed ID: 21712239 [TBL] [Abstract][Full Text] [Related]
27. [Short-course antibiotic regimens: Up-to-date]. Dinh A; Bouchand F; Salomon J; Bernard L Rev Med Interne; 2016 Jul; 37(7):466-72. PubMed ID: 26775641 [TBL] [Abstract][Full Text] [Related]
28. Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Allahverdiyev AM; Kon KV; Abamor ES; Bagirova M; Rafailovich M Expert Rev Anti Infect Ther; 2011 Nov; 9(11):1035-52. PubMed ID: 22029522 [TBL] [Abstract][Full Text] [Related]
29. Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections. Huang SS; Lee SC; Lee N; See LC; Tsai MH; Shieh WB J Microbiol Immunol Infect; 2007 Apr; 40(2):134-40. PubMed ID: 17446961 [TBL] [Abstract][Full Text] [Related]
30. Rising bacterial resistance to common antibiotics in Al Ain, United Arab Emirates. Al-Kaabi MR; Tariq WU; Hassanein AA East Mediterr Health J; 2011 Jun; 17(6):479-84. PubMed ID: 21796964 [TBL] [Abstract][Full Text] [Related]
31. Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage. Chen LY; Chen TC; Chen YH; Lin CY; Lin WR; Lu PL J Microbiol Immunol Infect; 2011 Oct; 44(5):352-7. PubMed ID: 21524975 [TBL] [Abstract][Full Text] [Related]
32. [Completing a course of drug therapy is necessary to combat the infection, not to discourage emergence of resistance]. van der Meer JW; Natsch S Ned Tijdschr Geneeskd; 2004 Aug; 148(35):1720-2. PubMed ID: 15468900 [TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of the ESKAPE pathogens. Pendleton JN; Gorman SP; Gilmore BF Expert Rev Anti Infect Ther; 2013 Mar; 11(3):297-308. PubMed ID: 23458769 [TBL] [Abstract][Full Text] [Related]
34. Mechanisms of bacterial resistance to antimicrobial agents. Stratton CW J Med Liban; 2000; 48(4):186-98. PubMed ID: 11214188 [TBL] [Abstract][Full Text] [Related]
35. Antimicrobial drug resistance in Taiwan. Huang YT; Hsueh PR Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S174-8. PubMed ID: 19013350 [TBL] [Abstract][Full Text] [Related]
36. Biofilm-associated infections: antibiotic resistance and novel therapeutic strategies. Sun F; Qu F; Ling Y; Mao P; Xia P; Chen H; Zhou D Future Microbiol; 2013 Jul; 8(7):877-86. PubMed ID: 23841634 [TBL] [Abstract][Full Text] [Related]
37. Antimicrobial peptides: their physicochemical properties and therapeutic application. Kang SJ; Kim DH; Mishig-Ochir T; Lee BJ Arch Pharm Res; 2012 Mar; 35(3):409-13. PubMed ID: 22477186 [TBL] [Abstract][Full Text] [Related]
38. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. McDonald LC Clin Infect Dis; 2006 Jan; 42 Suppl 2():S65-71. PubMed ID: 16355319 [TBL] [Abstract][Full Text] [Related]
39. [Antimicrobial resistance after antibiotic use in animals--impact on human health]. Sundsfjord A; Sunde M Tidsskr Nor Laegeforen; 2008 Nov; 128(21):2457-61. PubMed ID: 19096469 [TBL] [Abstract][Full Text] [Related]
40. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Zavascki AP; Carvalhaes CG; Picão RC; Gales AC Expert Rev Anti Infect Ther; 2010 Jan; 8(1):71-93. PubMed ID: 20014903 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]